Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 45-51 , 15 May 2010

GM1 ganglioside in Parkinson's disease: Results of a five year open study

  • Jay S. Schneider

      Affiliations

    • Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, 521 JAH, Philadelphia, PA 19107, United States. Tel.: +1 215 503 0370; fax: +1 215 923 3808.
    • ,
  • Stephanie Sendek

      Affiliations

    • Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • ,
  • Constantine Daskalakis

      Affiliations

    • Biostatistics Section, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • ,
  • Franca Cambi

      Affiliations

    • Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Current address: Department of Neurology, University of Kentucky, Lexington, KY, United States.

Received 29 October 2009 ,Revised 2 February 2010 ,Accepted 8 February 2010.

References 

  1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442
  2. Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmstead County project. Neurology. 1993;43:1918–1926
  3. Olanow CW, Schapira AH, Agid Y. Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol. 2003;53(Suppl. 3):S1–S2
  4. Olanow CW, Rascol O. Early rasagiline treatment slows decline in the ADAGIO delayed start study. Ann Neurol. 2008;64(Suppl. 12):S68
  5. Skaper SD, Leon A, Toffano G. Ganglioside function in the development and repair of the nervous system. Mol Neurobiol. 1989;3:173–199
  6. Nagai Y, Tsugi S. Cell biological significance of gangliosides in neural differentiation and development: critique and proposals. In:  Ledeen RW,  Hogan EL,  Tettamanti G,  Yates AJ,  Yu RK editor. New trends in ganglioside research. New York: Springer Verlag; 1988;p. 329–350
  7. Yu RK. Regulation of protein phosphorylation by gangliosides. In:  Ledeen RW,  Hogan EL,  Tettamanti G,  Yates AJ,  Yu RK editor. New trends in ganglioside research. New York: Springer Verlag; 1988;p. 461–472
  8. Rahmann H, Kortje KH, Probst W, Beitinger H, Mobius D, Ficker E. Calcium, gangliosides and neuronal modulation. In:  Ledeen RW,  Hogan EL,  Tettamanti G,  Yates AJ,  Yu RK editor. New trends in ganglioside research. New York: Springer Verlag; 1988;p. 473–486
  9. Jonsson G, Gorio A, Hallman H, Janigro D, Kojima H, Luthman J, et al. Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons after lesion by selective neurotoxins. J Neurosci Res. 1984;12:459–475
  10. Hadjiconstantino M, Rosetti ZL, Paxton RC, Neff NH. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharmacology. 1986;25:1075–1077
  11. Tilson HA, Harry GJ, Nanry K, Hudson PM, Hong JS. Ganglioside interactions with the dopaminergic system of rats. J Neurosci Res. 1988;19:88–93
  12. Oderfeld-Nowak B, Skup M, Ulas J, Jezierska M, Gradkowska M, Zarenba M. Effect of ganglioside GM1 treatment on post-lesion responses of cholinergic enzymes in rat hippocampus after various partial deafferentations. J Neurosci Res. 1984;12:409–420
  13. Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science. 1992;256:843–846
  14. Stull ND, Schneider JS, Iacovitti L. GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP+ induced damage: dependence on initial damage and time of treatment. Brain Res. 1994;640:308–315
  15. Tseng EE, Brock MV, Lange MS, Troncoso JC, Blue ME, Lowenstein CJ, et al. Monosialoganglioside GM1 inhibits neurotoxicity after hypothermic circulatory arrest. Surgery. 1998;124:298–306
  16. Kojima H, Gorio A, Janigro D, Jonsson G. GM1 ganglioside enhances regrowth of noradrenaline nerve terminals in rat cerebral cortex lesioned by the neurotoxin 6-hydroxydopamine. Neuroscience. 1984;13:1011–1022
  17. Ballough GPH, Cann FJ, Smith CD, Forster JS, Kling CE, Filbert MG. GM1 monosialoganglioside pretreatment protects against soman-induced seizure-related brain damage. Mol Chem Neuropathol. 1998;34:1–23
  18. Pope-Coleman A, Tinker JP, Schneider JS. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse. 2000;36:120–128
  19. Herrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid Y, et al. GM1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience. 1993;56:965–972
  20. Schneider JS, Kean A, DiStefano L. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J Neurosci Res. 1995;42:117–123
  21. Schneider JS, Roeltgen DP, Mancall EL. Parkinson's disease: Improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology. 1998;50:1630–1636
  22. Figueras A, Morales-Olivas FJ, Capella D, Palop V, Laporte JR. Bovine gangliosides in acute polyneuropathy. BMJ. 1992;305:1330–1331
  23. Landi G, D'Alessandro R, Dossi BC. Guillain–Barré syndrome after exposure to gangliosides. BMJ. 1993;307:1463–1464
  24. Raschetti R, Maggini M, Popoli P, Caffari B, Da Cas R, Menniti-Ippolito F, et al. Gangliosides and Guillain–Barré syndrome. J Clin Epidemiol. 1995;48:1399–1405
  25. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute inflammatory demyelinating axonal Guillain–Barre´ syndrome with IgG antibodies against motor polyradiculoneuropathy. Ann Neurol. 1995;38:218–224
  26. Schneider JS, Roeltgen DP, Rothblat DS, Chapas-Crilly J, Seraydarian L, Rao J. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy. Neurology. 1995;45:1149–1154
  27. Yu RK, Saito RK, Zhang Y, Fiorentini R, Khin-Maung-Gyi F, Friday G. Analysis of serum anti-GM1 antibody titres in patients receiving GM1 therapy. Soc Neurosci Abstr. 1992;18:1472
  28. Granieri E, Casetta I, Govoni V, Tola MR, Paolino E, Rocca WA. Ganglioside therapy and Guillain–Barré syndrome: a historical cohort study in Ferrara, Italy fails to demonstrate an association. Neuroepidemiology. 1991;10:161–169
  29. Paolino E, Govoni V, Tola MR, Casetta I, Granieri E. Incidence of Guillain–Barré syndrome in Ferrara, Northern Italy, 1981–1987. Neuroepidemiology. 1991;10:105–111
  30. Matias-Guiu J, Martin R, Blanquer J, Gonzalez MJ, Falip R, Oltra A, et al. The incidence of Guillain–Barré syndrome and ganglioside intake in Alcoi Spain. Neuroepidemiology. 1993;12:58–60
  31. Govoni V, Granieri E, Tola MR, Paolino E, Casetta I, Fainardi E, et al. Exogenous gangliosides and Guillain–Barré syndrome. An observational study in the Local Health District of Ferrara, Italy. Brain. 1997;120:1123–1130
  32. Govoni V, Granieri E, Manconi M, Capone J, Casetta I. Is there a decrease in Guillain–Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy. J Neurol Sci. 2003;216:99–103
  33. van Sorge NM, Yuki N, Jansen MD, Nishimoto Y, Susuki K, Wokke JHJ, et al. Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits. J Neuroimmunol. 2007;182:116–123
  34. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, et al. Animal model of axonal Guillain–Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–720
  35. Lopez PHH, Villa AM, Sica REP, Nores GA. High affinity as a disease determinant factor in anti-GM1 antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies. J Neuroimmunol. 2002;128:69–76
  36. Amjad AI, Chen Z-W. Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy. J Neuroimmunol. 2007;188:34–38
  37. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology. 1985;35:291–295
  38. Goetz CG, Leurgans S, Raman R and the Parkinson Study Group. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in Early Parkinson's disease. Mov Disord. 2002;17:283–288
  39. Cornelli U, Panucci A, Zingali G, Kirschner G, Baggio C, Cogo R. Pharmacokinetics of GM1 ganglioside following parenteral administration. J Pharm Pharmacol. 1990;42:708–711
  40. Zajchowski LD, Robbins SM. Lipid rafts and little caves. Compartmentalized signaling in membrane microdomains. Eur J Biochem. 2002;269:737–752

PII: S0022-510X(10)00066-3

doi: 10.1016/j.jns.2010.02.009

Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 45-51 , 15 May 2010

Article Tools

* Image Usage & Resolution